Field cancerisation and radiotherapy: a case of treatment complications
Authors: Gerald B Fogarty, Elizabeth J Paton and David Christie
Published online: 2 October 2023
To the Editor: We congratulate Morton and colleagues1 on publishing data on volumetric modulated arc therapy (VMAT) in skin field cancerisation. In their case study, at 3.5 years after VMAT of bilateral arms, the number of new cancers arising in VMAT areas seems higher than non‐VMAT areas. The patient had required hundreds of treatments of many types for individual lesions before VMAT and was moving into wider field treatments as the disease became more aggressive. With the failure of all these treatments to provide long term control of his skin cancers, now systemic therapy warrants consideration.
In our view, the implication that VMAT increased the rate of malignancy is problematic, as the overall pace of his disease was growing and the location of the new lesions was increasingly focused on heavily sun‐damaged and pre‐treated areas. Fortunately, the recurrent lesions were salvaged by plastic surgery. VMAT would have likely increased surgical difficulty. However, all the numerous previous therapies would also have contributed to that problem.
The authors and the Journal reviewers could have considered including the treating radiation and medical oncologists as co‐authors on the original article. With the advent of VMAT and systemic treatments for patients with aggressive skin field cancerisation, multimodality care has become the standard of care and modern articles describing prospective data on VMAT have shown high success rates and low toxicity and reflect the cooperation between specialties in their co‐authorship.2,3
Holding off VMAT until ten‐year data are available from a prospective trial is unrealistic and may lead to withholding of effective treatment. It is not industry standard for skin field cancerisation, as other recent trials routinely report one‐year primary endpoints.4 Prospective trials are needed, and we look forward to further multidisciplinary collaborations.
Competing interests
References
- Morton SK, Ozluer S, Muir J. Field cancerisation and radiotherapy: a case of treatment complications. Med J Aust 2023; 219: 12‐14. https://www.mja.com.au/journal/2023/219/1/field‐cancerisation‐and‐radiotherapy‐case‐treatment‐complications
- Potter AE, Baker C, Shumack S, et al; National Dermatology Radiation Oncology Registry (NDROR) investigators and sites. Preliminary efficacy and safety analysis: 12‐month results in 83 patients using a novel approach of widefield radiation therapy for extensive skin field cancerization with or without keratinocyte cancers. J Dermatolog Treat 2022; 33: 2634‐2642.
- Fogarty GB, Young S, Lo S, O'Toole J, Wanklyn M, Wong D, Sinclair S, Gottschalk G, Guitera P, Shumack S. (2021). Field‐based radiotherapy using volumetric modulated arc therapy (VMAT) for skin field cancerisation (SFC) — outcomes from 100 consecutive fields. Int J Radiol Radiat Ther 2021; 8: 13‐24.
- Jansen MHE, Kessels JPHM, Nelemans PJ, et al. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med 2019; 380: 935‐946.
Challenges and Opportunities for Strong and Dynamic Foundations in the Australian Cancer Plan
Ashley M. Hopkins, Andrew Rowland, Natansh D. Modi, Ceara Rickard, Mark Haseloff, Norma B. Bulamu, Imogen Ramsey, Niranjan Bidargaddi, Ganessan Kichenadasse, Michael J. Sorich, Kalinda E. Griffiths, Aideen McInerney-Leo, David M. Roder, Raymond J. Chan
Opportunities and Challenges to Achieving the Australian Cancer Plan Goal of World Class Health Systems for Optimal Cancer Care
Carolyn Ee, Ria Joseph, Elise Button, Stacey George, Makala Castelli, David Currow, Prue Cormie, Olivia Farrer, Michael Jefford, Nicolas H. Hart, Chad Y. Han, Deidre D. Morgan, Michael P. Osborn, Candice Oster, Joel Rhee, Anna Ugalde, Eric Yeung, Catherine Paterson
Maximising Cancer Prevention and Early Detection in the Australian Cancer Plan: Where Are We Now and What Should Come Next?
Erin L. Symonds, Billie Bonevski, Richard Edwards, Nathan J. Harrison, Sana Ishaque, Nicole M. Rankin, Sibel Saya, Renee J. Smith, Carolyn Ee
An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres
Sarah Childs, David Ma, Anthony Rodrigues, Jennifer Massey, Rasha Cosman, Venessa Chin, Laila Girgis, James Lynam, Peter Lau, Barbara Withers, Anthony M. Joshua, Ben Tran, Jayesh Desai, Simon J. Harrison, John Moore, Jia Liu
Peritoneal Tuberculosis and Chronic Myeloid Leukaemia: A Case of Hickam's Dictum
Zayn Al-Timimi, Gem Chew, Martin Browne, Christiaan Mostert
From Ambition to Action: Closing Policy, Equity and Implementation Gaps in the Australian Cancer Plan's ‘Enhanced Consumer Experience’
Carla Thamm, Elise Button, Oluwaseyifunmi A. Agbejule, Reegan Knowles, Karen van Gorp, Mark B. Pinkham, Meinir Krishnasamy, Alexandra L. McCarthy, Raymond J. Chan